Zentek signs US ZenGUARD licensing deal
Zentek (NASDAQ:ZTEK) said it has secured a pathway to sell its ZenGUARD enhanced air filtration media in the United States through an exclusive eight-year licensing agreement with Applied Silver.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Zentek (NASDAQ:ZTEK) said it has secured a pathway to sell its ZenGUARD enhanced air filtration media in the United States through an exclusive eight-year licensing agreement with Applied Silver.
Alicia Levine, chief investment officer at BNY Wealth, expects an upswing in volatility over the next few months, but sees a broadening of earnings driving the S&P 500 to 8,000 by the end of the year.
Roadzen (NASDAQ:RDZN) reported its best quarter and fiscal year with fourth quarter revenue of $16.1 million, up 42% year over year and 12% sequentially.
Tonix Pharmaceuticals (NASDAQ:TNXP) said it enrolled the first patient in HORIZON, a Phase 2, randomized, double-blind, placebo-controlled study of TNX-102 SL 5.6 mg for adults with major depressive disorder.
HP (NYSE:HPQ) announced a strategic partnership with OpenAI to deploy its Frontier enterprise AI platform across HP’s global business operations.
Artivion (NYSE:AORT) announced that the U.S. Food and Drug Administration has granted premarket approval for its AMDS Hybrid Prosthesis for the treatment of acute DeBakey Type I aortic dissections with malperfusion.
Helus Pharma (NASDAQ:HELP) reported fiscal 2026 results with cash of $157.3 million as of March 31, 2026.
Neurogene (NASDAQ:NGNE) reported updated Phase 1/2 clinical data showing 47 total developmental milestone gains across 10 participants treated with NGN-401 gene therapy for Rett syndrome.
Martin Marietta (NYSE:MLM) said it will combine with Lhoist North America in a transaction valued at about $13.5 billion, structured as a mix of cash and stock consideration.
Rocket Lab (NASDAQ:RKLB) agreed to acquire Iridium (NASDAQ:IRDM) in a transaction valuing the combined deal at about $8 billion enterprise value, combining cash, stock, and structured consideration for shareholders.
Talawar Therapeutics and JATT II (NASDAQ:JATT) have entered into a definitive business combination agreement to create a Nasdaq-listed biotechnology company expected to trade as TLWR in the second half of 2026.
Andy Burnham, who is likely to be the UK's next prime minister following Keir Starmer's decision to resign, outlines plans to decentralize power in a bid to boost the economy and raise living standards. "I am going to give Britain the circuit breaker it needs by building a more collaborative politics," Burnham says during a speech in Manchester.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade